NanoViricides, Inc. Anticipates FluCide™ Drug Candidates to be Effective Against H7N9

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC) (the "Company") said it anticipates that the oral and injectable FluCide™ drug candidates would be effective against the novel H7N9 strain that has caused human fatalities in China in recent months. Both the injectable FluCide drug for use in severely ill patients with influenza, and the oral FluCide drug for less sick out-patients bear a virus-binding ligand that mimics sialic acid. Moreover, this ligand is capable of substituting for both the mammalian form (sialyl-alpha2,6-gal-) or the avian form (sialyl-alpha2,3-gal-). Since the novel H7N9 (2013) virus is transitioning from avian to human host, the dual biomimetic capability of our FluCide ligand should have a favorable impact.